Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) has issued an announcement.
Jiangsu Recbio Technology has completed the full circulation of its H shares, converting 141,953,489 previously unlisted shares into H shares that began trading in Hong Kong on April 30, 2026. Following the conversion, the company’s share capital remains at 626,075,702 shares, but the proportion of H shares has surged from 50.50% to 73.17%, while domestic and unlisted foreign shares have been reduced, significantly increasing the stock’s free float and liquidity for international investors.
The move reshapes the company’s shareholder structure, with domestic shares falling from 47.59% to 26.83% and unlisted foreign shares being eliminated, potentially broadening the investor base and enhancing price discovery in the Hong Kong market. The company has cautioned shareholders and potential investors to exercise care when dealing in its securities amid the transition, underscoring that the change could impact trading dynamics and valuation in the near term.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a biotechnology company incorporated in Jiangsu Province, China, whose H shares are listed on the Stock Exchange of Hong Kong. The company operates through a mix of domestic shares and H shares, giving it access to both onshore and international capital markets.
Average Trading Volume: 8,603
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.44B
For a thorough assessment of 2179 stock, go to TipRanks’ Stock Analysis page.